1. Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model
   Masahito Masato et al, 2021, Scientific Reports CrossRef
2. Prostaglandin E2Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors
   Giovanna Petrucci et al, 2011, Journal of Pharmacology and Experimental Therapeutics CrossRef
3. Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy
   Muzammal Hussain et al, 2012, Pharmacological Research CrossRef
4. Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology
   Hedi Harizi, 2013, Cellular & Molecular Immunology CrossRef
5. Expression of Prostanoid EP3 Receptors in Oral Squamous Epithelium and Oral Squamous Cell Carcinoma
   Muhammad Kashif et al, 2015, Pathology Research International CrossRef
6. Mucopenetrating Janus Nanoparticles For Field-Coverage Oral Cancer Chemoprevention
   Nahal Habibi et al, 2023, Pharmaceutical Research CrossRef
7. The roles of the COX2/PGE2/EP axis in therapeutic resistance
   Dali Tong et al, 2018, Cancer and Metastasis Reviews CrossRef
8. Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR)
   Yao Ye et al, 2020, Journal of Cancer Research and Clinical Oncology CrossRef
9. Therapeutic implications of disorders of cell death signalling: membranes, micro‐environment, and eicosanoid and docosanoid metabolism
   J Davidson et al, 2012, British Journal of Pharmacology CrossRef
10. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2
    M. Dolores Salvado et al, 2012, Trends in Molecular Medicine CrossRef
11. Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma
    Walaa Hamed Shaker Nasry et al, 2021, Frontiers in Oncology CrossRef
12. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities
    Monika E. Freiser et al, 2013, Immunologic Research CrossRef
13. Enamel Matrix Derivative Suppresses Chemokine Expression in Oral Epithelial Cells
    Layla Panahipour et al, 2023, International Journal of Molecular Sciences CrossRef
14. Role of COX-2/PGE2 Mediated Inflammation in Oral Squamous Cell Carcinoma
    Walaa Nasry et al, 2018, Cancers CrossRef
15. The EP4 antagonist, L‐161,982, induces apoptosis, cell cycle arrest, and inhibits prostaglandin E2‐induced proliferation in oral squamous carcinoma Tca8113 cells
    Xiaohui Li et al, 2017, Journal of Oral Pathology & Medicine CrossRef
16. The Immune System in Head and Neck Squamous Cell Carcinoma: Interactions and Therapeutic Opportunities
    Paolo Serafini et al, 2014, Advances in Tumor Immunology and Immunotherapy CrossRef
17. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation
    Aline Correa Abrahao et al, 2010, Oral Oncology CrossRef
18. Potential Use of G Protein-Coupled Receptor-Blocking Monoclonal Antibodies as Therapeutic Agents for Cancers
    Deron R. Herr, 2012, International Review of Cell and Molecular Biology Volume 297 CrossRef
19. International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress
    D. F. Woodward et al, 2011, Pharmacological Reviews CrossRef
20. Prostaglandin Pathways: Opportunities for Cancer Prevention and Therapy
    Qiushi Wang et al, 2022, Cancer Research CrossRef